Merck Surpasses Expectations in Q2 CY2026 with Revenue Growth

Guavy AI Editorial Team Published August 4, 2026

Instruments

MRK

Merck (NYSE:MRK) reported better-than-expected revenue in Q2 CY2026, with sales up 5.1% year on year to $16.61 billion.

The company expects the full year's revenue to be around $66.8 billion, close to analysts' estimates.

Its non-GAAP loss of $0.13 per share was 49.5% above analysts' consensus estimates.

The Wire

Keep reading for free.

You've read 3 free articles in the last 24 hours. Create a free account for unlimited access, no card required.

Create free account Already have an account? Sign in

No spam. Unsubscribe anytime.

Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

GUAVY

Real-time market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

Terms Privacy Policy